Legal experts say Congress should give FDA new power to respond to shortages of critical drugs, floating the ideas of letting FDA temporarily re-purpose a drug license to another company, akin to NIH's march-in rights, and allowing importation from unregistered foreign manufacturers. The suggestions came a week after pharmaceutical engineers released a manufacturer-spearheaded drug shortage prevention plan that drew some praise from FDA and European regulatory officials. Charleston School of Law Professor William Janssen discussed the re-purposing idea at a...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.